AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24382782 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) treatment for 90 days, including six courses of low-dose daily rIL-2 followed by 3-day high-dose boluses.
Number of subjects: 214
Study 24382782 — intervention group
Group type: COMPARATOR
Intervention: Observation (no further therapy).
Number of subjects: 214
Study 24382782 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interleukin-2 (rIL-2) treatment for 90 days.
Number of subjects: 214
Study 21993078 — intervention group
Group type: EXPERIMENTAL
Intervention: arzoxifene 20 mg/d
Number of subjects: 9354
Study 21993078 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9354
Study 19018977 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg
Number of subjects: 40
Study 19018977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17959989 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA) with propofol, nitrous oxide/sevoflurane, and fentanyl
Number of subjects: 40
Study 17959989 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA) with bupivacaine hydrochloride
Number of subjects: 40
Study 15846259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel added to standard fibrinolytic therapy
Number of subjects: 0
Study 15846259 — intervention group
Group type: COMPARATOR
Intervention: Standard fibrinolytic therapy alone (placebo control)
Number of subjects: 0
Study 15846259 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 12217154 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconferencing as an alternative to general practitioner referral to a hospital specialist
Number of subjects: 3170
Study 12217154 — intervention group
Group type: COMPARATOR
Intervention: General practitioner referral to a hospital specialist
Number of subjects: 3170
Study 9708644 — intervention group
Group type: COMPARATOR
Intervention: CE (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day)
Number of subjects: 81
Study 9708644 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP (Cyclophosphamide 4 g/m2, Etoposide 600 mg/m2, G‐CSF 6 microg/kg/day, Cisplatin 105 mg/m2)
Number of subjects: 81
Study 9708644 — intervention group
Group type: EXPERIMENTAL
Intervention: CEP
Number of subjects: 81
Study 9708644 — intervention group
Group type: COMPARATOR
Intervention: CE and CEP
Number of subjects: 81
Study 7893440 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrovector-transduced autologous fibroblasts (VTAF) administered via three intramuscular injections at 2-week intervals.
Number of subjects: 4
Study 2712548 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin, 400 mg alone
Number of subjects: 8
Study 2712548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g concurrently with norfloxacin, 400 mg
Number of subjects: 8
Study 2712548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate, 1 g followed by norfloxacin, 400 mg, 2 h later
Number of subjects: 8
Study 996785 — intervention group
Group type: EXPERIMENTAL
Intervention: Zeta potential reduction test in cystic fibrosis genotypes
Number of subjects: 0
Study 996785 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal individuals)
Number of subjects: 0
Study 31989232 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction with periareolar excision (delivery technique)
Number of subjects: 20
Study 31989232 — intervention group
Group type: COMPARATOR
Intervention: Liposuction with pull-through technique
Number of subjects: 20
Study 31989232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 20
Study 30540337 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 21768
Study 30540337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21768
Study 30540337 — intervention group
Group type: COMPARATOR
Intervention: Evolocumab vs Placebo
Number of subjects: 21768
Study 26923543 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation and plyometric training (PPT)
Number of subjects: 24
Study 26061330 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus S‐1 and cisplatin (NCS)
Number of subjects: 62
Study 26061330 — intervention group
Group type: COMPARATOR
Intervention: S‐1 and cisplatin (CS) alone
Number of subjects: 62
Study 23273358 — intervention group
Group type: EXPERIMENTAL
Intervention: MI Paste Plus
Number of subjects: 115
Study 23273358 — intervention group
Group type: EXPERIMENTAL
Intervention: PreviDent fluoride varnish
Number of subjects: 115
Study 23273358 — intervention group
Group type: COMPARATOR
Intervention: Usual home care (control)
Number of subjects: 115
Study 21451365 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis using a resource-saving diagnostic staining panel for precursor cell neoplasms.
Number of subjects: 193
Study 21451365 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization guidelines for lineage determination and subtyping of precursor cell leukemia.
Number of subjects: 193
Study 18789762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI (LGI) meal (GI=36)
Number of subjects: 8
Study 18789762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-GI (HGI) meal (GI=83)
Number of subjects: 8
Study 18789762 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) (low energy sugar-free jelly)
Number of subjects: 8
Study 16829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Full attention during picture study
Number of subjects: 0
Study 16829485 — intervention group
Group type: COMPARATOR
Intervention: Divided attention during picture study
Number of subjects: 0
Study 16829485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual exclusivity instructions
Number of subjects: 0
Study 16829485 — intervention group
Group type: COMPARATOR
Intervention: No mutual exclusivity instructions
Number of subjects: 0
Study 15231443 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD with comorbid anxiety disorders (n = 18)
Number of subjects: 48
Study 15231443 — intervention group
Group type: COMPARATOR
Intervention: All depressed patients (n = 33)
Number of subjects: 48
Study 15231443 — intervention group
Group type: COMPARATOR
Intervention: Pure mood disorders (n = 15)
Number of subjects: 48
Study 15231443 — intervention group
Group type: COMPARATOR
Intervention: Pure anxiety disorders (n = 15)
Number of subjects: 48
Study 15231443 — intervention group
Group type: EXPERIMENTAL
Intervention: All patient groups
Number of subjects: 48
Study 15231443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol response
Number of subjects: 48
Study 11199952 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone patients
Number of subjects: 18
Study 11199952 — intervention group
Group type: COMPARATOR
Intervention: Drug-free healthy controls
Number of subjects: 18
Study 9017356 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin (99 U microcrystalline solid insulin)
Number of subjects: 11
Study 9017356 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (10 U regular insulin)
Number of subjects: 11
Study 8313397 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 220
Study 8313397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 8313397 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine (150 mg/day)
Number of subjects: 220
Study 3791560 — intervention group
Group type: COMPARATOR
Intervention: Single bolus injection of 300 mg/m2 (S arm)
Number of subjects: 72
Study 3791560 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 80 mg/m2 daily for 5 days (D x 5 arm)
Number of subjects: 72
Study 31332902 — intervention group
Group type: EXPERIMENTAL
Intervention: Levomilnacipran (LVM)
Number of subjects: 29
Study 31332902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29654011 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity Treatment Burden Questionnaire (MTBQ)
Number of subjects: 1546
Study 27054932 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM diagnosed using Carpenter-Coustan criteria
Number of subjects: 958
Study 27054932 — intervention group
Group type: COMPARATOR
Intervention: Untreated women
Number of subjects: 958
Study 24788850 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace interventions
Number of subjects: 36
Study 23771007 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-point-touch fitting approach
Number of subjects: 61
Study 23771007 — intervention group
Group type: COMPARATOR
Intervention: Apical touch fitting approach
Number of subjects: 61
Study 23771007 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 61
Study 23771007 — intervention group
Group type: COMPARATOR
Intervention: Nipple cones
Number of subjects: 61
Study 23771007 — intervention group
Group type: COMPARATOR
Intervention: Oval cones
Number of subjects: 61
Study 20978374 — intervention group
Group type: EXPERIMENTAL
Intervention: MRK adenovirus type 5 gag/pol/nef HIV vaccine
Number of subjects: 0
Study 20978374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18405162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (blood-letting puncture and cupping at Ashi points)
Number of subjects: 399
Study 18405162 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 399
Study 15641767 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-based vaccines (plasmid DNA and recombinant adenoviral vector carrying human PSMA)
Number of subjects: 0
Study 12870340 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy combined with Mitomycin C and removed suture
Number of subjects: 75
Study 12870340 — intervention group
Group type: COMPARATOR
Intervention: Normal trabeculectomy (Control)
Number of subjects: 75
Study 10484239 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-regulating treatment
Number of subjects: 21100000
Study 10484239 — intervention group
Group type: COMPARATOR
Intervention: NCEP guidelines
Number of subjects: 21100000
Study 10484239 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol-lowering drug therapy
Number of subjects: 21100000
Study 8698614 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blinded capsules containing different levels of vitamin C and beta-carotene
Number of subjects: 90
Study 1928974 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled SK&F 104353 (average nebulized dose, 893 micrograms)
Number of subjects: 6
Study 1928974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study 6126285 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 0
Study 6126285 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 6126285 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 0
Study 6126285 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 0
Study 31596129 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted training group
Number of subjects: 230
Study 31596129 — intervention group
Group type: COMPARATOR
Intervention: Non-targeted training group
Number of subjects: 230
Study 28679182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine (Group A)
Number of subjects: 157
Study 28679182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychotherapy (Group B)
Number of subjects: 157
Study 28679182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapoxetine and Group Psychotherapy (Group C)
Number of subjects: 157
Study 25328091 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin powder formulation
Number of subjects: 602
Study 25328091 — intervention group
Group type: COMPARATOR
Intervention: Metformin tablets formulation
Number of subjects: 602
Study 23882107 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled breathing techniques
Number of subjects: 46
Study 23882107 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 22563177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy (CFC)
Number of subjects: 295
Study 22563177 — intervention group
Group type: COMPARATOR
Intervention: Non-cap-fitted colonoscopy (NCF)
Number of subjects: 295
Study 19152203 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone doses >= 60 mg/day
Number of subjects: 2831
Study 19152203 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible dosing strategies
Number of subjects: 2831
Study 18545119 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve blockade
Number of subjects: 52
Study 18545119 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metamizole
Number of subjects: 52
Study 15790607 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS)
Number of subjects: 82
Study 15790607 — intervention group
Group type: COMPARATOR
Intervention: Depot GnRH analogue
Number of subjects: 82
Study 12006728 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary treatment
Number of subjects: 0
Study 12006728 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 10223255 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of Memory Impairment Scale (AMIS)
Number of subjects: 203
Study 10223255 — intervention group
Group type: COMPARATOR
Intervention: Difference scores and clinical ratings
Number of subjects: 203
Study 7492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Q‐switched ruby laser (wavelength, 694 nm; beam diameter, 5.0 mm) at a fluence of 6.0 J/cm2
Number of subjects: 9
Study 7492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency‐doubled Q‐switched neodymium:YAG laser (wavelength, 532 nm; beam diameter, 2.0 mm) at a fluence of 6.0 J/cm2
Number of subjects: 9
Study 7492131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lasers
Number of subjects: 9
Study 2401126 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 mg/kg/day caffeine (low dose)
Number of subjects: 9
Study 2401126 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/kg/day caffeine (high dose)
Number of subjects: 9
Study 2401126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 363334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide alone
Number of subjects: 49
Study 363334 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 400 mg/day
Number of subjects: 49
Study 363334 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and spironolactone
Number of subjects: 49
Study 363334 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 49
Study 363334 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (up to 100 mg/day)
Number of subjects: 49
Study 31502382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylera® (2 capsules) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Number of subjects: 99
Study 31502382 — intervention group
Group type: COMPARATOR
Intervention: Gastrus® (2 x 10^8 CFU L reuteri DSM 17 938 plus 2 x 10^8 CFU L reuteri ATCC PTA 6475) plus 250 mg each of tetracycline and metronidazole, pantoprazole 20 mg b.i.d., for 10 days
Number of subjects: 99
Study 31502382 — intervention group
Group type: EXPERIMENTAL
Intervention: Pylera®
Number of subjects: 99
Study 31502382 — intervention group
Group type: COMPARATOR
Intervention: Gastrus®
Number of subjects: 99
Study 28145948 — intervention group
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty after ACL reconstruction
Number of subjects: 122
Study 28145948 — intervention group
Group type: COMPARATOR
Intervention: Control group (primary osteoarthritis, no history of ligament reconstruction)
Number of subjects: 122
Study 26371270 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention arm
Number of subjects: 1980
Study 26371270 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 1980
Study 23352174 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoenriched formula (IEF group)
Number of subjects: 108
Study 23352174 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous placebo diet (Con group)
Number of subjects: 108
Study 21436393 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS) group
Number of subjects: 16
Study 21436393 — intervention group
Group type: COMPARATOR
Intervention: No RAS group (internally paced stepping)
Number of subjects: 16
Study 20032538 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐alpha2a treatment
Number of subjects: 14
Study 20032538 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine monotherapy
Number of subjects: 14
Study 17234020 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and activation program (EAP) in addition to usual care (UC)
Number of subjects: 0
Study 17234020 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 0
Study 14710212 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² and cisplatin 80 mg/m² on day 1 (DC)
Number of subjects: 108
Study 14710212 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m² on day 8 and irinotecan 60 mg/m² on day 1 and 8 (DI)
Number of subjects: 108
Study 11689751 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric (ANTHRO) estimates of total body and leg fat-free mass (FFM)
Number of subjects: 77
Study 11689751 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy x-ray absorptiometric (DEXA) estimates of total body and leg fat-free mass (FFM)
Number of subjects: 77
Study 11689751 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak VO2 corrected for FFMANTHRO
Number of subjects: 77
Study 11689751 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak VO2 corrected for FFMDEXA
Number of subjects: 77
Study 9424908 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-adrenaline solution (Group I)
Number of subjects: 30
Study 9424908 — intervention group
Group type: COMPARATOR
Intervention: Fibrin sealant-Beriplast (Group II)
Number of subjects: 30
Study 7524291 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-4238
Number of subjects: 0
Study 7524291 — intervention group
Group type: COMPARATOR
Intervention: CMA (Chlormadinone Acetate)
Number of subjects: 0
Study 3284530 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (Timunox) 1 ml (50 mg) plus lidocaine 1 ml (2%), once a week for 5 weeks
Number of subjects: 122
Study 3284530 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone depot 1 ml (40 mg) plus lidocaine 1 ml (2%)
Number of subjects: 122
Study 31791087 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill exercise (‐15%)
Number of subjects: 9
Study 31791087 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill exercise (+15%)
Number of subjects: 9
Study 31791087 — intervention group
Group type: EXPERIMENTAL
Intervention: Level exercise (+1%)
Number of subjects: 9
Study 29246818 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of DMPA
Number of subjects: 401
Study 29246818 — intervention group
Group type: COMPARATOR
Intervention: Clinic administration of DMPA
Number of subjects: 401
Study 29246818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 401
Study 28355979 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy care
Number of subjects: 148
Study 28355979 — intervention group
Group type: EXPERIMENTAL
Intervention: SBST administered at different time points
Number of subjects: 148
Study 28355979 — intervention group
Group type: EXPERIMENTAL
Intervention: SBST at baseline
Number of subjects: 148
Study 24434827 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily feedback messages (DFB group; n = 70)
Number of subjects: 210
Study 24434827 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral intervention for weight loss (both groups)
Number of subjects: 210
Study 22509750 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% MF gel
Number of subjects: 118
Study 22509750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MF gel
Number of subjects: 118
Study 22509750 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% MF gel
Number of subjects: 118
Study 22509750 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 118
Study 21365405 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program (quarterly follow-up by a hospital pharmacist for 9 months)
Number of subjects: 197
Study 21365405 — intervention group
Group type: COMPARATOR
Intervention: No pharmaceutical care (control group)
Number of subjects: 197
Study 18440341 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 6325
Study 16390859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNB) with ropivacaine 0.25%
Number of subjects: 10
Study 16390859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNB) with lidocaine 1%
Number of subjects: 10
Study 16390859 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (no intervention)
Number of subjects: 10
Study 16390859 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNB)
Number of subjects: 10
Study 14576536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg succinylcholine
Number of subjects: 200
Study 14576536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg succinylcholine
Number of subjects: 200
Study 14576536 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg succinylcholine
Number of subjects: 200
Study 14576536 — intervention group
Group type: COMPARATOR
Intervention: 0.0 mg/kg succinylcholine (saline control)
Number of subjects: 200
Study 14576536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 mg/kg succinylcholine
Number of subjects: 200
Study 14576536 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.24 mg/kg succinylcholine
Number of subjects: 200
Study 10630716 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician advice
Number of subjects: 774
Study 10630716 — intervention group
Group type: COMPARATOR
Intervention: Control group (no brief physician advice)
Number of subjects: 774
Study 8960574 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 22516
Study 1413942 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-sympathomimetics + transcutaneous dorsal nerve stimulation (TNS)
Number of subjects: 114